EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient‐derived orthotopic xenografts, cell lines and tumor entities

Edgar Creus-Bachiller, Juana Fernández-Rodríguez, Miriam Magallón-Lorenz, Sara Ortega-Bertran, Susana Navas-Rutete, Cleofe Romagosa, Tulio M Silva, Maria Pané iD, Anna Estival, Diana Perez Sidelnikova, Mireia Morell, Helena Mazuelas und 7 weitere

Molecular Oncology · 2024

DOI: 10.1002/1878-0261.13534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Edgar Creus-Bachiller und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. Hauptthemen laut MEDLINE: Neurofibrosarcoma, Nerve Sheath Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centro de Investigación Biomédica en Red de Cáncer, Departament de Salut, Generalitat de Catalunya, Fundació la Marató de TV3.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft‐tissue sarcomas with a poor survival rate, presenting either sporadically or in the context of neurofibromatosis type 1 (NF1). The histological diagnosis of MPNSTs can be challenging, with different tumors exhibiting great histological and marker expression overlap. This heterogeneity could be partly responsible for the observed disparity in treatment response due to the inherent diversity of the preclinical models used. For several years, our group has been generating a large patient‐derived orthotopic xenograft (PDOX) MPNST platform for identifying new precision medicine treatments. Herein, we describe the expansion of this platform using six primary tumors clinically diagnosed as MPNSTs, from which we obtained six additional PDOX mouse models and three cell lines, thus generating three pairs of in vitro–in vivo models. We extensively characterized these tumors and derived preclinical models, including genomic, epigenomic, and histological analyses. Tumors were reclassified after these analyses: three remained as MPNSTs (two being classic MPNSTs), one was a melanoma, another was a neurotrophic tyrosine receptor kinase ( NTRK )‐rearranged spindle cell neoplasm, and, finally, the last was an unclassifiable tumor bearing neurofibromin‐2 ( NF2 ) inactivation, a neuroblastoma RAS viral oncogene homolog ( NRAS ) oncogenic mutation, and a SWI/SNF‐related matrix‐associated actin‐dependent regulator of chromatin ( SMARCA4 ) heterozygous truncated variant. New cell lines and PDOXs faithfully recapitulated histology, marker expression, and genomic characteristics of the primary tumors. The diversity in tumor identity and their specific associated genomic alterations impacted treatment responses obtained when we used the new cell lines for testing compounds against known altered pathways in MPNSTs. In summary, we present here an extension of our MPNST precision medicine platform, with new PDOXs and cell lines, including tumor entities confounded as MPNSTs in a real clinical scenario. This platform may constitute a useful tool for obtaining correct preclinical information to guide MPNST clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeurofibrosarcomaNerve Sheath NeoplasmsHumansMiceAnimalsPrecision MedicineHeterograftsCell LineDNA HelicasesNuclear ProteinsTranscription Factors

Stichwörter der Autor:innen

MPNSTNF1PDOXcellular modelstreatment responsetumor entities

Substanzen

SMARCA4 protein, humanDNA HelicasesNuclear ProteinsTranscription Factors

Autor:innen und Institutionen

  • Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Mouse Lab, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain.
  • Department of Pathology, Hospital Vall d'Hebron, Barcelona, Spain.

ORCID-Profile: Maria Pané, Eduard Serra, Conxi Lázaro

Förderung

  • Centro de Investigación Biomédica en Red de Cáncer
  • Departament de Salut, Generalitat de Catalunya
  • Fundació la Marató de TV3
  • Fundación Científica Asociación Española Contra el Cáncer
  • Fundación PROYECTO NEUROFIBROMATOSIS
  • Instituto de Salud Carlos III

Zitieren

APA

Creus-Bachiller, E., Fernández-Rodríguez, J., Magallón-Lorenz, M., Ortega-Bertran, S., Navas-Rutete, S., Romagosa, C., Silva, T. M., Pané, M., Estival, A., Perez Sidelnikova, D., Morell, M., Mazuelas, H., Carrió, M., Lausová, T., Reuss, D., Gel, B., Villanueva, A., Serra, E., & Lázaro, C. (2024). Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient‐derived orthotopic xenografts, cell lines and tumor entities. Molecular Oncology. https://doi.org/10.1002/1878-0261.13534

Vancouver

Creus-Bachiller E, Fernández-Rodríguez J, Magallón-Lorenz M, Ortega-Bertran S, Navas-Rutete S, Romagosa C, et al. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient‐derived orthotopic xenografts, cell lines and tumor entities. Molecular Oncology. 2024. doi:10.1002/1878-0261.13534

BibTeX
@article{CreusBachiller2024,
  author = {Creus-Bachiller, Edgar and Fernández-Rodríguez, Juana and Magallón-Lorenz, Miriam and Ortega-Bertran, Sara and Navas-Rutete, Susana and Romagosa, Cleofe and Silva, Tulio M and Pané, Maria and Estival, Anna and Perez Sidelnikova, Diana and Morell, Mireia and Mazuelas, Helena and Carrió, Meritxell and Lausová, Tereza and Reuss, David and Gel, Bernat and Villanueva, Alberto and Serra, Eduard and Lázaro, Conxi},
  title = {Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient‐derived orthotopic xenografts, cell lines and tumor entities},
  journal = {Molecular Oncology},
  year = {2024},
  doi = {10.1002/1878-0261.13534}
}
Kostenlos starten →